CD40:CD40L Assay Service
●
Target
CD40:CD40L
●
Description
Screening and/or profiling inhibitor compounds against CD40:CD40L binding in a homogeneous biochemical assay.
●
Synonyms
T cell antigen Gp39, TNF related activation protein, TRAP, tumor necrosis factor ligand superfamily member 5, TNFSF5, CD154, CD40, CD40 Molecule
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
TR-FRET
●
Reference Compounds and IC50
Anti-CD40L Antibody, 1 nM
●
Assay Principle
The CD40:CD40L TR-FRET Assay is designed to measure binding activity of CD40 to CD40L for screening and profiling applications using TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer). It utilizes Terbium-labeled donor and a labeled acceptor to complete the TR-FRET pairing. The CD40:CD40L TR-FRET Assay is performed in a 384-well format as follows. A sample containing terbium-labeled donor, dye-labeled acceptor, CD40, CD40L, and an inhibitor is incubated for 90 minutes. The fluorescence intensity is then measured using a fluorescence reader. In the presence of binding of CD40 to CD40L, energy transfer occurs due to the proximity of the donor and acceptor. Disruption of the binding results in decrease of energy transfer. Fluorescence intensity at λ=665 nm corresponds directly to the binding of CD40 to CD40L.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
CD40: P25942; CD40L: P29965
●
Background
CD40 (cluster of differentiation 40), also known as TNFRSF5 ((tumor necrosis factor)-receptor superfamily 5) is a type I transmembrane protein involved in the activation of antigen presenting cells (APCs), such as dendritic cells, B cells and macrophages. It can also be found in epithelial and endothelial cells, and tumor cells. CD40L (CD40 ligand), also known as TNFSF5 and CD154, is a type II membrane glycoprotein that exists in cells in membrane bound (mCD40L) and soluble (sCD40L) forms. It is found at high levels in activated CD4+ T cells, and at lower levels in Th1, Th2, Th17 and Tregs. Expression can also be induced in NK cells, CD8+ T cells, basophils, and others. CD40 and CD40L are stimulatory immune checkpoints, and their signaling is mediated by different TRAF (TNF receptor associated factor), in a cell and stimuli dependent mode. For example, it mediates the activation of the NF-κB (nuclear factor kappa-B) pathway. CD40 is implicated in Hyper Ig-M immunodeficiency, where IgM is found at high levels in the serum, while other IgG are present at lower-than-normal levels, and patients have higher risk of developing autoimmune diseases and cancer. The role of CD40 and CD40L as immune checkpoints makes them highly attractive targets in cancer therapy, and several clinical trials using anti-CD40 or anti-CD40L agonist antibodies or increasing their expression are underway targeting both hematological and solid tumors. The inhibition of CD40:CD40L interaction is also clinically relevant, and clinical trials have been focusing on treatment options for lupus, rheumatoid arthritis and ALS (amyotrophic lateral sclerosis). Further studies and development of refined therapies will continue to benefit the cancer therapy field and patients suffering from autoimmune disorders.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
